Will a new tenofovir prodrug for the treatment of HIV reduce the risk of nephrotoxicity?
other
Where this comes from
- Record sourced from PubMed, PMID 26759035.
- Also identified by DOI 10.1016/j.kint.2015.11.014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The widely used antiretroviral agent tenofovir disoproxil fumarate has been associated with proximal tubular injury and decreased glomerular filtration rate in HIV-infected individuals. Phase 3 trials of a new prodrug, tenofovir alafenamide, suggest a lower potential for kidney injury.
Medical subject headings
- Adenine
- Antiviral Agents
- Kidney Tubules, Proximal
- Prodrugs